Identifying Drugs to

We combine extensive data sets and expertise to
identify potential blockbusters and therapeutic game-

Download the report

Drugs to Watch™ showcases drugs recently launched or likely to enter the market this year that are forecast to become blockbusters within five years and/or to transform treatment paradigms (blockbuster is defined by the common $1 billion annual sales milestone).

To identify this year’s Drugs to Watch 2024 list, we drew from expertise from over 160 Clarivate analysts covering hundreds of diseases, drugs and markets and 11 integrated data sets that span the R&D and commercialization lifecycle.

Drug selection criteria:

  1. Candidate drugs in phase 2 or phase 3 trials, at pre-registration or registration stage, or already launched early in 2023 were selected for analysis, including drugs launched for a new indication that could be particularly impactful on the industry; drugs launched prior to 2023 were excluded.
  2. We then filtered the dataset for drugs that had total forecast sales of $1 billion or more in 2027.

Clarivate experts then manually evaluated each drug in its individual context, based on factors such as expected approval or launch dates, competitive landscape, regulatory status, trial results, market dynamics and other factors and added novel drugs that, while likely to fall short of blockbuster status, are poised to be therapeutic game-changers.

From there, we determined 13 Drugs to Watch in 2024.

arrow_forwardSee Drugs to Watch 2024

Data sources and contributors

Since 2013, Clarivate has applied proprietary technologies, tools and techniques trusted by its global life sciences customers to produce the annual Drugs to Watch report.

Cortellis™ solutions

Get actionable life sciences intelligence and insights across an array of solutions. The Cortellis suite of solutions helps research and development, portfolio strategy and business development and regulatory and compliance professionals gather and assess the information you need to discover innovative drugs, differentiate your treatments and increase chances of successful regulatory approval.

arrow_forwardFind out more about Cortellis

Additional Life Sciences and Healthcare data behind Drugs to Watch

In addition to the Cortellis suite, Clarivate analysts also integrated data from other Life Sciences and Healthcare solutions from Clarivate.
The BioWorld™ suite of news services delivers actionable intelligence on the most innovative therapeutics and medical technologies in development, helping life science industry professionals and investors stay on top of this fast-changing field.

arrow_forwardFind out more about BioWorld


Clarivate Real World Data sets and solutions support customers across the drug, device and diagnostic lifecycle with timely and in-depth intelligence to help them answer business challenges and better meet patient unmet needs.

arrow_forwardFind out more about Real World Data

Web of Science™

The Web of Science is the world’s largest publisher-neutral citation index and research intelligence platform. It organizes the world’s research information to enable academia, corporations, publishers and governments to accelerate the pace of research.

arrow_forwardFind out more about Web of Science

Derwent Innovation™

Built by IP experts and data scientists, Derwent Innovation is a market-leading patent research and analytics platform delivering globally trusted patents and scientific literature and providing the insights the world’s most innovative companies rely on for creating, protecting and commercializing their innovation.

arrow_forwardFind out more about Derwent Innovation

From innovation to bottom line

Access global intelligence, advanced analytics and global experts from Clarivate.

Contact our team